## Clinical Diagnosis and Management Strategy **Key Point:** The patient presents with **progressive keratoconus** — a 22-year-old with 18 months of documented progression (frequent prescription changes), cone-shaped corneal protrusion, stromal thinning, and marked astigmatism. In a young patient with active progression, **corneal collagen cross-linking (CXL)** is the most appropriate next step to halt disease progression. ### Why Corneal Cross-Linking Is the Answer 1. **Documented progression:** The hallmark indication for CXL is **evidence of progression** — this patient has had 18 months of progressive refractive changes, which is the primary trigger for intervention. 2. **Young age:** At 22 years, this patient is at peak risk for rapid progression. CXL is most effective and most urgently indicated in young patients with active disease. 3. **Mechanism:** Riboflavin (vitamin B2) acts as a photosensitizer; when activated by UVA (370 nm), it generates reactive oxygen species that create new covalent bonds between collagen fibrils, increasing corneal stiffness by ~300% (Wollensak et al., 2003). 4. **Goal of CXL:** To **halt progression**, not to improve vision. After stabilization, RGP lenses or other optical correction can be optimized. 5. **Current guidelines (AAO, ISAKPS):** CXL is the standard of care for progressive keratoconus in patients with adequate corneal thickness (>400 µm at thinnest point) and no significant scarring. ### Management Hierarchy in Keratoconus | Stage | Clinical Features | Management | |-------|-------------------|-------------| | Early/Mild, stable | Mild astigmatism, no progression | Spectacles or soft lenses | | **Progressive (any stage)** | **Documented progression** | **Corneal cross-linking (CXL) — FIRST** | | Moderate, stable | Significant astigmatism, reduced VA | Rigid gas-permeable (RGP) contact lenses | | Advanced | Marked thinning, scarring, poor RGP tolerance | Specialty lenses (scleral) | | End-stage | Corneal scarring, opacity, RGP intolerance | Penetrating keratoplasty | **Clinical Pearl:** The critical distinction is **progression vs. stable disease**. RGP lenses are the optical correction of choice for moderate stable keratoconus, but when a young patient shows active progression, CXL must be performed first to prevent further deterioration. Fitting RGP lenses without addressing progression allows the disease to worsen unchecked. (Kanski's Clinical Ophthalmology, 9th ed.) **High-Yield:** CXL is **contraindicated** if corneal thickness < 400 µm at the thinnest point, or if there is significant corneal scarring. The Dresden protocol (0.1% riboflavin + 3 mW/cm² UVA for 30 min) remains the gold standard. ### Why Other Options Are Incorrect - **RGP contact lenses (D):** Provide optical correction but do **not halt progression**. In a patient with documented active progression, CXL must precede or accompany optical rehabilitation. - **Penetrating keratoplasty (A):** Reserved for end-stage disease with corneal scarring, opacity, or intolerance to contact lenses. Premature in this case. - **Photorefractive keratectomy (C):** **Absolutely contraindicated** in keratoconus. Ablative procedures further thin and weaken the cornea, accelerating ectasia. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.